ArticleCureus2025
Outcomes in Heart Failure With Improved Ejection Fraction Following Implantable Cardioverter-Defibrillator Placement for Primary Prevention.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Limited data exist on outcomes in heart failure with improved ejection fraction (HFimpEF) following implantation of cardiac devices, such as implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy (CRT). In this contemporary analysis, we utilize the most current American Heart Association (AHA)/American College of Cardiology (ACC) 2022 definition of HFimpEF to evaluate hospitalization and mortality in this population. Methods This retrospective study analyzed patients who received ICD or CRT for primary prevention at a non-tertiary hospital between 2019 and 2022. Data were extracted from the Device Implant Registry, assessing demographics, clinical parameters, echocardiography, and device type. Improvement in ejection fraction (EF) was assessed using a follow-up echocardiogram performed at least six months after device implantation. The outcomes measured included the one-year and overall (3.6 years) rates of hospitalization and mortality from the date of ICD/CRT insertion to October 1, 2024. Results Our study comprised 54 patients with a repeat echocardiogram after at least six months post-ICD/CRT placement to assess left ventricular ejection fraction (EF). Those with HFimpEF had fewer one-year admissions (22.2%) compared to those with persistent heart failure with reduced EF (HFrEF) (48.2%) (p < 0.05). Overall hospitalization rates were also significantly lower (59.3%) in HFimpEF versus 85.19% in HFrEF (p < 0.05). Heart failure accounted for 50% of the cardiac-related hospitalizations. Mortality rates were reduced (14.8%) in the HFimpEF group compared with 29.63% in HFrEF, but there was no significant statistical difference between the groups. A lower brain natriuretic peptide (BNP) is predictive of both improved EF (p < 0.01) and decreased mortality (p < 0.01). Conclusions Patients with myocardial recovery post-ICD/CRT have better prognoses than those with persistent HFrEF. Uncontrolled heart failure remains the predominant factor contributing to hospitalization after device implantation among our cohort. Implementing an outpatient standardized clinical interval summary that incorporates scheduled BNP assessment may represent a cost-effective strategy to enhance the care of patients with HFimpEF in non-tertiary healthcare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.